Compare TLN & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLN | BBIO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7B | 15.9B |
| IPO Year | 2014 | 2019 |
| Metric | TLN | BBIO |
|---|---|---|
| Price | $304.58 | $78.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 25 |
| Target Price | ★ $432.08 | $86.33 |
| AVG Volume (30 Days) | 865.6K | ★ 2.1M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,581,000,000.00 | $502,076,000.00 |
| Revenue This Year | $59.63 | $89.45 |
| Revenue Next Year | $16.08 | $73.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 22.03 | ★ 126.26 |
| 52 Week Low | $301.45 | $48.78 |
| 52 Week High | $451.28 | $93.42 |
| Indicator | TLN | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 34.89 | 42.41 |
| Support Level | N/A | $78.64 |
| Resistance Level | $405.34 | $85.42 |
| Average True Range (ATR) | 15.44 | 2.55 |
| MACD | -3.11 | -0.63 |
| Stochastic Oscillator | 5.01 | 5.94 |
Talen Energy Corp is an independent power producer and energy infrastructure company based in the United States. It owns and operates several gigawatts of power infrastructure in the United States, including 2.2GW of nuclear power and a dispatchable fossil fleet. The company produces and sells electricity, capacity, and ancillary services into wholesale U.S. power markets, with its generation fleet principally located in the Mid-Atlantic, Ohio, and Montana. Talen's operating segments are: PJM and Others. The PJM segment, which generates maximum revenue, is engaged in electricity generation, marketing activities, and commodity risk and fuel management within the PJM market and is comprised of Susquehanna and Talen's natural gas and coal generation facilities in PJM.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.